Brought to you by 
Kite, Pfizer enter clinical trial collaboration
22 Oct 2021
Executive Summary
Gilead Sciences Inc.'s Kite Pharma Inc. is teaming up with Pfizer Inc. in a trial collaboration to study the safety and efficacy of Kite's Yescarta (axicabtagene ciloleucel) in combination with Pfizer's utomilumab (PF05082566) for treating patients with refractory large B-cell lymphoma.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Trial Collaborations
- R&D (No Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Kite, Pfizer enter clinical trial collaboration
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice